Fenbendazole kills parasites by destroying their internal structural framework and starving them of energy. It belongs to the benzimidazole class of dewormers, and its primary target is a protein called beta-tubulin, which parasites need to maintain cell structure and absorb nutrients. The drug is approved for use in cattle, dogs, and other animals, but has no FDA approval for human use.
How It Disrupts Cell Structure
Every cell relies on a scaffolding system made of tiny tubes called microtubules. These tubes hold the cell’s shape, move materials around internally, and play a critical role in cell division. Fenbendazole binds to beta-tubulin, one of the two building blocks of microtubules, at a specific site known as the colchicine binding site. Once fenbendazole latches on, tubulin subunits can no longer assemble into functional tubes.
In lab studies, fenbendazole caused a measurable decrease in the amount of assembled tubulin inside treated cells. The microtubule network surrounding the cell nucleus lost its structural integrity, leaving behind a distorted framework. This collapse has cascading consequences: cells can’t divide properly, can’t transport nutrients internally, and can’t maintain their shape. For a parasite, this damage is fatal.
Fenbendazole is considered a moderate microtubule destabilizer. It doesn’t demolish the entire network as aggressively as some other compounds that bind the same site. Instead, it causes a partial but sustained disruption, enough to cripple parasite cells while being relatively gentle on the host animal’s cells. That selectivity comes from the fact that fenbendazole binds much more tightly to parasite beta-tubulin than to the mammalian version of the same protein.
How It Starves Parasites of Energy
Beyond structural damage, fenbendazole cuts off a parasite’s fuel supply. Intestinal worms depend heavily on glucose absorption from their host’s gut, and the transport systems they use to pull in glucose rely on intact microtubules. When fenbendazole disrupts the microtubule network, those glucose transporters can no longer function properly. The parasite’s glycogen stores (its energy reserves) deplete rapidly, and without the ability to replenish them, the worm essentially starves.
This two-pronged attack, structural collapse plus energy starvation, is what makes benzimidazoles so effective against a broad range of parasites. The worms lose the ability to hold onto the gut wall, stop feeding, and are eventually expelled from the host’s body.
What It Treats in Animals
Fenbendazole is licensed for use in cattle, dogs, cats, horses, and other livestock. The standard dose for beef and dairy cattle is 5 mg per kilogram of body weight, which covers lungworms, stomach worms (including barberpole worms and brown stomach worms), and a range of intestinal worms such as hookworms, threadneck worms, and nodular worms. A higher dose of 10 mg per kilogram is used in beef cattle to treat tapeworms and a dormant larval stage of stomach worms that the standard dose doesn’t reach.
In dogs, fenbendazole is commonly sold under the brand name Panacur and treats roundworms, hookworms, whipworms, and certain tapeworms. It’s typically given over multiple consecutive days rather than as a single dose, which helps catch parasites at different life stages.
What Happens After It’s Swallowed
Fenbendazole is poorly absorbed from the gut. In studies on alpacas (which are commonly used as a model for oral drug absorption), only about 16% of an oral dose reached the bloodstream, and peak blood levels didn’t occur until roughly 10 hours after dosing. The drug’s half-life was around 23 hours, meaning it clears the body within a few days.
Once absorbed, the liver rapidly converts fenbendazole into two metabolites through a stepwise oxidation process. The first metabolite, oxfendazole, is itself an active dewormer and is sometimes used as a standalone drug. Oxfendazole is then further converted into a second, inactive metabolite called fenbendazole sulfone. This rapid metabolism is one reason the drug has relatively low systemic exposure: most of it is broken down before it can accumulate.
The Cancer Research Question
Fenbendazole gained public attention after anecdotal reports suggested it might have anticancer properties. Lab research has explored several possible mechanisms. In cancer cell studies, fenbendazole increased levels of p53, a protein that acts as one of the body’s main tumor suppressors. When p53 levels rise, it triggers a chain of events that slows cancer cell metabolism. Specifically, p53 activation reduced the activity of hexokinase 2 (a key enzyme cancer cells use to process glucose at high speed), decreased glucose consumption, and lowered the energy output of treated cancer cells.
Separate research in non-small cell lung cancer models found that fenbendazole inhibited GLUT1, a transporter protein that cancer cells rely on to pull glucose into the cell at the elevated rates their rapid growth demands. Blocking this transporter effectively puts cancer cells on an energy diet. A 2025 study in breast cancer cells showed that fenbendazole triggered a specific form of cell death called pyroptosis through this p53-glucose metabolism pathway.
These findings are limited to lab dishes and animal models. The American Cancer Society notes that fenbendazole has not been tested in human clinical studies, and experts agree that scientific data does not yet exist about whether it is safe or effective for people with cancer. The FDA has never approved fenbendazole for any human use.
Known Safety Risks
In animals at standard veterinary doses, fenbendazole has a wide safety margin and rarely causes significant side effects. The picture is less clear for humans self-administering the drug, which some people have done after reading about the cancer claims online.
Several reports have documented liver toxicity in people taking fenbendazole. In one published case, a 67-year-old man who had been taking three 1-gram packets of fenbendazole granules three times per week developed severe drug-induced liver injury. His liver enzymes climbed to more than 50 times normal levels, and a biopsy showed broad zones of liver cell death with inflammatory changes. After stopping the drug, his liver enzymes dropped by more than half within a week and fully normalized within three months.
A clinical trial of oxfendazole, the active metabolite that fenbendazole converts into, also reported liver enzyme abnormalities. And albendazole, a closely related benzimidazole that is approved for human use, commonly causes mild and transient liver enzyme elevations, with rare cases of clinically apparent liver injury. The pattern across this drug class suggests the liver is a consistent vulnerability point, particularly at doses higher than those used in veterinary medicine.